This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n12http://linked.opendata.cz/resource/drugbank/drug/DB05838/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05838/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05838/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05838/identifier/bindingdb/

Statements

Subject Item
n2:DB05838
rdf:type
n3:Drug
n3:description
OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence.
n3:generalReferences
# Nakamura S, Hirano T, Tsujimae K, Aoyama M, Kondo K, Yamamura Y, Mori T, Tominaga M: Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats. J Pharmacol Exp Ther. 2000 Dec;295(3):1005-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11082435
n3:group
investigational
n3:indication
Investigated for use/treatment in nocturia (frequent nighttime urination) and urinary incontinence.
owl:sameAs
n6:DB05838
dcterms:title
OPC-51803
adms:identifier
n8:2302070 n9:DB05838 n11:50117486 n12:3038506
n3:IUPAC-Name
n4:271B47AF-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B47B5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B47B4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B47B1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B47B2-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B47B3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B47AD-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B47AB-363D-11E5-9242-09173F13E4C5 n4:271B47AE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B47AC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B47BB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B47BC-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B47B6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B47B7-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B47B9-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B47B8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B47BA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B47C1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B47C3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B47C4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B47C0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B47BF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B47C2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B47B0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B47BD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B47BE-363D-11E5-9242-09173F13E4C5